on February 3, 2005
Published online before print February 3, 2005, doi: 10.1161/01.ATV.0000158380.44231.fe
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on May 3, 2004
Accepted on January 21, 2005
High Serum Levels of Advanced Glycation End Products Predict Increased Coronary Heart Disease Mortality in Nondiabetic Women but not in Nondiabetic Men. A Population-Based 18-Year Follow-Up Study
Bente K. Kilhovd ;
From the Diabetes Research Centre, Aker and Ullevål University Hospitals and Department of Medicine (B.K.K., T.J.B., K.F.H.) and the Hormone Laboratory (P.A.T., K.I.B.), Aker University Hospital HF, Oslo; the Department of Medicine (A.J., S.L., M.L.), University of Kuopio and Kuopio University Hospital; and the Department of Medicine (T.R.), University of Turku, Finland.
* To whom correspondence should be addressed. E-mail: markku.laakso{at}kuh.fi.
Background--Advanced glycation end products (AGEs), modification products of glycation or glycoxidation of proteins and lipids, have been linked to premature atherosclerosis in patients with diabetes as well as in nondiabetic subjects.
Methods and Results--Serum levels of AGEs were measured with an immunoassay in samples obtained at baseline examination of a random sample of 1141 nondiabetic individuals (535 men and 606 women), aged 45 to 64 years, living in Kuopio, East Finland, or Turku, West Finland in 1982 to 1984. After 18 years of follow-up, all-cause mortality, cardiovascular disease (CVD), and coronary heart disease (CHD) mortality were registered on the basis of copies of death certificates. Multivariate Cox regression model showed a significant association of serum AGEs with all-cause (P=0.012), CVD (P=0.018), and CHD (P=0.008) mortality in women but not in men. Fasting serum AGEs in the highest quartile were an independent risk factor for all-cause (hazards ratio [HR], 1.90; 95% CI, 1.16 to 3.11; P=0.011) and CHD (HR, 6.51; 95% CI, 1.78 to 23.79; P=0.005) mortality in women, even after the adjustment for confounding factors, including highly sensitive C-reactive protein.
Conclusions--The present study is the first to show that serum levels of AGEs can predict total, CVD, and CHD mortality in nondiabetic women.
Key words: advanced glycation end products • coronary heart disease • cardiovascular disease • mortality
This article has been cited by other articles:
 |
|
 |
|
  H. Vlassara, W. Cai, S. Goodman, R. Pyzik, A. Yong, X. Chen, L. Zhu, T. Neade, M. Beeri, J. M. Silverman, et al. Protection against Loss of Innate Defenses in Adulthood by Low Advanced Glycation End Products (AGE) Intake: Role of the Antiinflammatory AGE Receptor-1 J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4483 - 4491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Lindsey, F. Cipollone, S. M Abdullah, and D. K Mcguire Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 7 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Maksimowicz-McKinnon, F. Selzer, S. Manzi, K. E. Kip, S. R. Mulukutla, O. C. Marroquin, T. C. Smitherman, L. H. Kuller, D. O. Williams, and M. C. M. Wasko Poor 1-Year Outcomes After Percutaneous Coronary Interventions in Systemic Lupus Erythematosus: Report From the National Heart, Lung, and Blood Institute Dynamic Registry Circ Cardiovasc Interv, December 1, 2008; 1(3): 201 - 208. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. D. Abel, S. E. Litwin, and G. Sweeney Cardiac Remodeling in Obesity Physiol Rev, April 1, 2008; 88(2): 389 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W.L. Hartog, A. A. Voors, C. G. Schalkwijk, J. Scheijen, T. D.J. Smilde, K. Damman, S. J.L. Bakker, A. J. Smit, and D. J. van Veldhuisen Clinical and prognostic value of advanced glycation end-products in chronic heart failure Eur. Heart J., December 1, 2007; 28(23): 2879 - 2885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. de Leeuw, R. Graaff, R. de Vries, R. P. Dullaart, A. J. Smit, C. G. Kallenberg, and M. Bijl Accumulation of advanced glycation endproducts in patients with systemic lupus erythematosus Rheumatology, October 1, 2007; 46(10): 1551 - 1556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Uribarri, W. Cai, M. Peppa, S. Goodman, L. Ferrucci, G. Striker, and H. Vlassara Circulating Glycotoxins and Dietary Advanced Glycation Endproducts: Two Links to Inflammatory Response, Oxidative Stress, and Aging J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2007; 62(4): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Koyama, T. Shoji, S. Fukumoto, K. Shinohara, T. Shoji, M. Emoto, K. Mori, H. Tahara, E. Ishimura, R. Kakiya, et al. Low Circulating Endogenous Secretory Receptor for AGEs Predicts Cardiovascular Mortality in Patients With End-Stage Renal Disease Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 147 - 153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Brunner, M. J. Shipley, D. R. Witte, J. H. Fuller, and M. G. Marmot Relation Between Blood Glucose and Coronary Mortality Over 33 Years in the Whitehall Study Diabetes Care, January 1, 2006; 29(1): 26 - 31. [Abstract] [Full Text] [PDF]
|
|